Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 12/20 | 0.51 |
| ▸ | CCR4 | P51679 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5576159 | 1.00 | CCR5 (0.51) | CCR5CCR4KCNH2FAAHBCHE | |
| SCHEMBL5576041 | 0.87 | CCR5 (0.52) | CCR5CCR4KCNH2FAAHBCHE | |
| SCHEMBL5576031 | 0.87 | CCR5 (0.52) | CCR5CCR4KCNH2FAAHBCHE | |
| SCHEMBL5573913 | 0.86 | CCR5 (0.71) | CCR5CCR4KCNH2 | |
| SCHEMBL5573908 | 0.86 | CCR5 (0.71) | CCR5CCR4KCNH2 | |
| SCHEMBL14614407 | 0.80 | CCR5 (0.58) | CCR5CCR4FAAHBCHEACHE | |
| SCHEMBL4627849 | 0.79 | CCR5 (0.46) | CCR5CCR4KCNH2MCHR1 | |
| SCHEMBL4627844 | 0.79 | CCR5 (0.46) | CCR5CCR4KCNH2MCHR1 | |
| SCHEMBL5576320 | 0.78 | CCR5 (0.59) | CCR5CCR4KCNH2 | |
| SCHEMBL5576306 | 0.78 | CCR5 (0.59) | CCR5CCR4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | CCR5 1/4885CCR4 2/4885KCNH2 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.